logo-loader
viewNanobiotix SA

Nanobiotix strengthens US team

“These high level profiles will contribute to reinforce Nanobiotix’s presence in the US."

Cancer research graphic
The group plans to initiate a Phase I/II trial in three US-based oncology sites.

Late clinical-stage cancer therapy group Nanobiotix (EPA:NANO) has strengthened its US leadership team.

The group has appointed Dr Mihail Obrocea as the head of US clinical development and Noёl Kurdi as the director of investor relations.

Obrocea joins Nanobiotix from US-based SFJ Pharmaceuticals Group, where he held the role of vice president of Clinical & Medical Affairs.

Kurdi joins Nanobiotix from the Trout Group & Trout Capital. She served as a senior associate, providing strategic investor relations counsel to biotech companies seeking access to the US and international capital markets.

“These high level profiles will contribute to reinforce Nanobiotix’s presence in the US by strengthening its clinical development and by leveraging US investors potential to continue the growth of the company,” said the statement late Monday.

Nanobiotix has successfully filed its Investigational New Drug application in the US for its prostate cancer drug NBTXR3 and plans to initiate a Phase I/II trial in three US-based oncology sites.

Quick facts: Nanobiotix SA

Price: 18.1 GBX

EPA:NANO
Market: EPA
Market Cap: £51.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Protech Home Medical has a full treasury as they look for rapid growth in...

Protech Home Medical (CVE: PTQ- OTCQX: PTQQF) CEO Greg Crawford joined Steve Darling from Proactive to discuss the home medical equipment industry company. That company provides devices like ventilators and oxygen concentrators. Crawford told Proactive the company just completed a large...

1 hour, 56 minutes ago

2 min read